The Effect of Adding Memantine to Clonidine in Reducing Withdrawal Symptoms in Opioid-Dependent Patients A Double-Blind Randomized Controlled Trial

被引:2
作者
Kheirabadi, Gholamreza [1 ]
Najafian, Narges [2 ]
Khodadadi, Farinaz [3 ]
机构
[1] Isfahan Univ Med Sci, Behav Sci Res Ctr, Sch Med, Hezar Jarib St, Esfahan 8145831451, Iran
[2] Isfahan Univ Med Sci, Dept Psychiat, Sch Med, Esfahan, Iran
[3] Isfahan Univ Med Sci, Behav Sci Res Ctr, Esfahan, Iran
关键词
memantine; clonidine; withdrawal symptoms; opium; addiction; ANTAGONIST MEMANTINE; EXPRESSION;
D O I
10.1097/JCP.0000000000001466
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective Addiction is a complex condition and a brain disease manifested by compulsive substance use despite its harmful consequence. Addicted individuals have an intense focus on using substances. This study aimed to investigate the effect of adding memantine to clonidine and buprenorphine in reducing withdrawal symptoms, compared with placebo, in drug-dependent patients (opium and heroin). Materials and Methods In this double-blind, randomized clinical trial study, 60 patients using opium or heroin were assigned to the intervention (n = 30) and control (n = 30) groups. Both groups were treated with buprenorphine and clonidine at the same dose in the detoxification process. The intervention group received memantine 10 mg daily for 10 days and then 20 mg daily for 21 days, and the control group received a placebo prepared in the same shape and size as memantine tablets. The severity of withdrawal symptoms was measured using the Short Opioid Withdrawal Scale over 3 weeks. Data analysis was performed using SPSS and descriptive and inferential tests. Results The results showed that despite memantine's superiority in controlling some withdrawal symptoms such as feeling sick, stomach pain, muscle spasm, and feeling cold, no significant difference was found between the 2 groups. There was also no statistically significant difference between the 2 groups in the total score of symptoms. Conclusions No specific advantage of memantine was found for reducing the symptoms of withdrawal syndrome in the present study. However, this drug was well tolerated without any evidence of serious or significant adverse effects.
引用
收藏
页码:644 / 649
页数:6
相关论文
共 31 条
  • [11] Effects of the NMDA receptor antagonist memantine on the expression and development of acute opiate dependence as assessed by withdrawal-potentiated startle and hyperalgesia
    Harris, Andrew C.
    Rothwell, Patrick E.
    Gewirtz, Jonathan C.
    [J]. PSYCHOPHARMACOLOGY, 2008, 196 (04) : 649 - 660
  • [12] Efficacy of buprenorphine and clonidine in opioid detoxification: A hospital-based study
    Jain, Neeraj
    Chavan, B. S.
    Sidana, Ajeet
    Das, Subhash
    [J]. INDIAN JOURNAL OF PSYCHIATRY, 2018, 60 (03) : 292 - 299
  • [13] Kamali M, 2015, PHYSIOL PHARMACOL, V19, P274
  • [14] Kleber Herbert D, 2007, Dialogues Clin Neurosci, V9, P455
  • [15] Kong EL., Narcotic Bowel Syndrome
  • [16] Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment
    Kosten, Thomas R.
    Baxter, Louis E.
    [J]. AMERICAN JOURNAL ON ADDICTIONS, 2019, 28 (02) : 55 - 62
  • [17] Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13
  • [18] Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review
    Kuszmaul, Amanda K.
    Palmer, Emma C.
    Frederick, Emily K.
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (01) : 145 - 152
  • [19] Low-dose memantine attenuated methadone dose in opioid-dependent patients: a 12-week double-blind randomized controlled trial
    Lee, Sheng-Yu
    Chen, Shiou-Lan
    Chang, Yun-Hsuan
    Chen, Po See
    Huang, San-Yuan
    Tzeng, Nian-Sheng
    Wang, Liang-Jen
    Lee, I. Hui
    Wang, Tzu-Yun
    Chen, Kao Chin
    Yang, Yen Kuang
    Hong, Jau-Shyong
    Lu, Ru-Band
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [20] Louis MO., Forest Pharmaceuticals